Merck Gardasil sBLA Gets Priority Review In Older Women
This article was originally published in The Pink Sheet Daily
Executive Summary
Company seeks approval of the vaccine for women ages 27 through 45.
You may also be interested in...
Novavax CEO Rahul Singhvi - An Interview With “The Pink Sheet” DAILY
Vaccine firm tells "The Pink Sheet" DAILY about its virus-like particles process for making vaccines and how its processes can be less expensive and require smaller facilities.
Novavax CEO Rahul Singhvi - An Interview With “The Pink Sheet” DAILY
Vaccine firm tells "The Pink Sheet" DAILY about its virus-like particles process for making vaccines and how its processes can be less expensive and require smaller facilities.
Merck Receives FDA “Complete Response” On Gardasil For Women 27-45
Firm also receives complete response to its sBLA for cross-protection.